RNA interference with zilebesiran for mild to moderate hypertension
JAMA
About The Study: In adults with mild to moderate hypertension, treatment with zilebesiran, an investigational RNA interference therapeutic, across a range of subcutaneous doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory systolic blood pressure at month three in this phase 2, randomized clinical trial.
Authors: George L. Bakris, M.D., of University of Chicago Medicine, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.0728)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.0728?guestAccessKey=ee26508a-9c86-4221-ae57-5e871eea1346&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021624
END
Authors: George L. Bakris, M.D., of University of Chicago Medicine, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.0728)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.0728?guestAccessKey=ee26508a-9c86-4221-ae57-5e871eea1346&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021624
END